FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308448747> ?p ?o ?g. }

• W4308448747 abstract "Introduction Immunotherapy has revolutionized metastatic Melanoma therapy. The most active regimen is combination therapy of Ipilimumab-Nivolumab (Ipi-Nivo) with response rates (RR) of ~60% and median overall survival (OS) of ~6 years. Immune-related adverse events (irAE) are common (~60% develop grade 3-4) and pose a challenge when treating frail patients. We sought to examine whether Ipi-Nivo therapy is feasible in elderly metastatic melanoma patients. Methods Electronic records of patients treated at the Ella Lemelbaum Institute with Ipi-Nivo between the years 2017-2021 were screened for age. Elderly patients were defined as age 75 and older (group A) and were matched with records of patients age &lt;75 (group B). Records were analyzed for baseline parameters, immunotherapy regimen, RR, toxicity and progression-free survival (PFS). Results Twenty-six relevant patients age &gt;75 (median 77) were identified and were matched to 34 younger patients (median age 57). No statistically significant differences were noted in terms of baseline parameters except for BRAF mutation status (group A 15%, group B 47%, p=0.008). Response rate in group A was 38% and is consistent with previously published data. Median PFS was the same for both groups (A = 5.5 months, B= 7.5 months, p=NS). Treatment was similarly tolerated: 35% of group A patients completed 4 cycles of therapy compared to 28% for group B (p=NS). Grade 2-4 irAE were the same (A=58%, B=66%, p=NS) and there was no difference in the need for hospitalization for G3-4 events between the groups. (A=63%, B=69%, p=NS). Further division into 4 age groups (&gt;80 vs 75-79 in group A and 65-74 vs &lt;65 in group B) found no difference in terms of response rate or G3-4 toxicity. Conclusion Ipilimumab-Nivolumab combination therapy in elderly metastatic Melanoma patients seems to be well tolerated and efficient in selected elderly patients based on performance status and comorbidities, just as in younger patients. This regimen seems to be a feasible treatment option for this age group." @default.
• W4308448747 created "2022-11-12" @default.
• W4308448747 creator A5009662153 @default.
• W4308448747 creator A5026746657 @default.
• W4308448747 creator A5026967523 @default.
• W4308448747 creator A5028871696 @default.
• W4308448747 creator A5040576722 @default.
• W4308448747 creator A5054364242 @default.
• W4308448747 creator A5058238015 @default.
• W4308448747 creator A5072955983 @default.
• W4308448747 date "2022-11-07" @default.
• W4308448747 modified "2023-10-17" @default.
• W4308448747 title "Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients" @default.
• W4308448747 cites W1556334181 @default.
• W4308448747 cites W2063410191 @default.
• W4308448747 cites W2097995306 @default.
• W4308448747 cites W2128035403 @default.
• W4308448747 cites W2129270330 @default.
• W4308448747 cites W2553340100 @default.
• W4308448747 cites W2560367415 @default.
• W4308448747 cites W2592144107 @default.
• W4308448747 cites W2610766845 @default.
• W4308448747 cites W2731921472 @default.
• W4308448747 cites W2736642458 @default.
• W4308448747 cites W2738867151 @default.
• W4308448747 cites W2753432434 @default.
• W4308448747 cites W2791133407 @default.
• W4308448747 cites W2792937256 @default.
• W4308448747 cites W2797675588 @default.
• W4308448747 cites W2808441345 @default.
• W4308448747 cites W2883070482 @default.
• W4308448747 cites W2891762335 @default.
• W4308448747 cites W2909679049 @default.
• W4308448747 cites W2911177533 @default.
• W4308448747 cites W2913383852 @default.
• W4308448747 cites W2955628118 @default.
• W4308448747 cites W3021590305 @default.
• W4308448747 cites W3023736474 @default.
• W4308448747 cites W3043703771 @default.
• W4308448747 cites W3046937944 @default.
• W4308448747 cites W3092162117 @default.
• W4308448747 cites W3096267580 @default.
• W4308448747 cites W3106036064 @default.
• W4308448747 cites W3138699402 @default.
• W4308448747 cites W3194855235 @default.
• W4308448747 cites W4282022545 @default.
• W4308448747 cites W4296904710 @default.
• W4308448747 doi "https://doi.org/10.3389/fonc.2022.1020058" @default.
• W4308448747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36419899" @default.
• W4308448747 hasPublicationYear "2022" @default.
• W4308448747 type Work @default.
• W4308448747 citedByCount "1" @default.
• W4308448747 countsByYear W43084487472023 @default.
• W4308448747 crossrefType "journal-article" @default.
• W4308448747 hasAuthorship W4308448747A5009662153 @default.
• W4308448747 hasAuthorship W4308448747A5026746657 @default.
• W4308448747 hasAuthorship W4308448747A5026967523 @default.
• W4308448747 hasAuthorship W4308448747A5028871696 @default.
• W4308448747 hasAuthorship W4308448747A5040576722 @default.
• W4308448747 hasAuthorship W4308448747A5054364242 @default.
• W4308448747 hasAuthorship W4308448747A5058238015 @default.
• W4308448747 hasAuthorship W4308448747A5072955983 @default.
• W4308448747 hasBestOaLocation W43084487471 @default.
• W4308448747 hasConcept C121608353 @default.
• W4308448747 hasConcept C126322002 @default.
• W4308448747 hasConcept C143998085 @default.
• W4308448747 hasConcept C197934379 @default.
• W4308448747 hasConcept C2777658100 @default.
• W4308448747 hasConcept C2777701055 @default.
• W4308448747 hasConcept C2780030458 @default.
• W4308448747 hasConcept C2781413609 @default.
• W4308448747 hasConcept C2781433595 @default.
• W4308448747 hasConcept C29730261 @default.
• W4308448747 hasConcept C2994587330 @default.
• W4308448747 hasConcept C502942594 @default.
• W4308448747 hasConcept C71924100 @default.
• W4308448747 hasConceptScore W4308448747C121608353 @default.
• W4308448747 hasConceptScore W4308448747C126322002 @default.
• W4308448747 hasConceptScore W4308448747C143998085 @default.
• W4308448747 hasConceptScore W4308448747C197934379 @default.
• W4308448747 hasConceptScore W4308448747C2777658100 @default.
• W4308448747 hasConceptScore W4308448747C2777701055 @default.
• W4308448747 hasConceptScore W4308448747C2780030458 @default.
• W4308448747 hasConceptScore W4308448747C2781413609 @default.
• W4308448747 hasConceptScore W4308448747C2781433595 @default.
• W4308448747 hasConceptScore W4308448747C29730261 @default.
• W4308448747 hasConceptScore W4308448747C2994587330 @default.
• W4308448747 hasConceptScore W4308448747C502942594 @default.
• W4308448747 hasConceptScore W4308448747C71924100 @default.
• W4308448747 hasLocation W43084487471 @default.
• W4308448747 hasLocation W43084487472 @default.
• W4308448747 hasLocation W43084487473 @default.
• W4308448747 hasLocation W43084487474 @default.
• W4308448747 hasOpenAccess W4308448747 @default.
• W4308448747 hasPrimaryLocation W43084487471 @default.
• W4308448747 hasRelatedWork W2588304536 @default.
• W4308448747 hasRelatedWork W2888298425 @default.
• W4308448747 hasRelatedWork W2891051134 @default.
• W4308448747 hasRelatedWork W2897550585 @default.
• W4308448747 hasRelatedWork W2899127460 @default.

• next